abcodia

Abcodia, founded in 2009, commercializes the ROCA Test, a proprietary blood test for ovarian cancer surveillance in high-risk women. The test, which tracks changes in the CA-125 biomarker over time using a statistical algorithm, is supported by strong clinical data showing earlier detection and improved surgical outcomes. The company has achieved key validation through NICE guidance and NHS adoption in specific regions, while also expanding access privately and internationally through partnerships. Its business model is centered on providing a diagnostic service to a well-defined, high-risk patient population.

Proprietary algorithm (Risk of Ovarian Cancer Algorithm) that interprets longitudinal measurements of the CA-125 biomarker in blood over time to calculate a personalized risk score for ovarian cancer.

The primary competitor is the current standard of care: risk-reducing salpingo-oophorectomy (RRSO). Other surveillance methods include annual transvaginal ultrasound and static CA-125 testing, which are less sensitive. The ROCA Test is differentiated by its algorithm-based, longitudinal approach and is the only test for this purpose with NICE endorsement for demonstrated accuracy. Emerging competition could come from novel multi-cancer early detection (MCED) blood tests, though their utility in high-risk, targeted surveillance is unproven.